+ All Categories
Home > Documents > Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Date post: 04-Feb-2016
Category:
Upload: ilana
View: 33 times
Download: 0 times
Share this document with a friend
Description:
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2. Chronic Obstructive Pulmonary Disease (COPD). WHO Report on the Global Tobacco Epidemic. According GOLD - PowerPoint PPT Presentation
31
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2
Transcript
Page 1: Chronic Obstructive Pulmonary Disease (COPD)

Andriy Lepyavko, MD, PhDDepartment of Internal Medicine № 2

Page 2: Chronic Obstructive Pulmonary Disease (COPD)

WHO Report on the Global Tobacco Epidemic

Page 3: Chronic Obstructive Pulmonary Disease (COPD)
Page 4: Chronic Obstructive Pulmonary Disease (COPD)

According GOLD COPD – this is disease which is

characterized by combination of clinical signs of chronic obstructive bronchitis (inflammation and narrowing of bronchi) and emphysema (changes of lung tissue structure).

Page 5: Chronic Obstructive Pulmonary Disease (COPD)

Permanent hyperactivity of parasympathetic Permanent hyperactivity of parasympathetic nervous system nervous system with hyperproduction of with hyperproduction of acetylcholine, bronchial spasm and hypersecretion acetylcholine, bronchial spasm and hypersecretion of mucusof mucus

Insufficiency of adrenal receptors in bronchial Insufficiency of adrenal receptors in bronchial wallswalls as the result of deep morphological changes as the result of deep morphological changes with bronchial hypersecretion, bronchial spasm and with bronchial hypersecretion, bronchial spasm and coughcough

Bronchial hyperreactivity Bronchial hyperreactivity which is characterized which is characterized by immune inflammation of bronchioles walls by immune inflammation of bronchioles walls

All that lead to:All that lead to: 1) 1) narrowing of bronchiolesnarrowing of bronchioles; ; 2) 2) development of emphysemadevelopment of emphysema

Page 6: Chronic Obstructive Pulmonary Disease (COPD)
Page 7: Chronic Obstructive Pulmonary Disease (COPD)
Page 8: Chronic Obstructive Pulmonary Disease (COPD)
Page 9: Chronic Obstructive Pulmonary Disease (COPD)
Page 10: Chronic Obstructive Pulmonary Disease (COPD)
Page 11: Chronic Obstructive Pulmonary Disease (COPD)
Page 12: Chronic Obstructive Pulmonary Disease (COPD)
Page 13: Chronic Obstructive Pulmonary Disease (COPD)

Severe smoking Occupational diseases Family anamnesis Chronic cough is the earliest sign of

COPD and arise earlier then dyspnea Sputum – as a rool in small amount, after

cough Dyspnea – persistent, progressive,

becomes worse during physical activity and in severe cases – even if patient is calm

Page 14: Chronic Obstructive Pulmonary Disease (COPD)

Central cyanosis, emphysematous chest, additional breathing muscles are necessary for breathing

Increasing of breathing rate, decreasing of its deepness, prolongation of expiration

Percussion: decreasing of heart dullness Auscultation: wheezing, dry rales, heart tones are

dull

Page 15: Chronic Obstructive Pulmonary Disease (COPD)

Investigation of external breathing (spyrometry);

Bronchodilatation test; Cytology of sputum; Blood analysis; X-ray; ECG; Blood gases

Investigation of external breathing FVC – max air volume which is expired during

forced expiration after max inspiration; FEV1 (<80 %) FEV1/FVC (<70 %) Peak flow (of expiration)

Page 16: Chronic Obstructive Pulmonary Disease (COPD)
Page 17: Chronic Obstructive Pulmonary Disease (COPD)
Page 18: Chronic Obstructive Pulmonary Disease (COPD)
Page 19: Chronic Obstructive Pulmonary Disease (COPD)
Page 20: Chronic Obstructive Pulmonary Disease (COPD)

Is necessary to find bronchial reversibility

Spyrometry has to be provided before and 15 min after inhalation of 400 mkg of Salbutamol (or 30-45 min – 80 mkg of Ipratropium)

Increasing of FEV1 more than 15 % tells us about reversibility

Page 21: Chronic Obstructive Pulmonary Disease (COPD)
Page 22: Chronic Obstructive Pulmonary Disease (COPD)
Page 23: Chronic Obstructive Pulmonary Disease (COPD)

Stage and severity  Signs

І, mild 

FEVІ ≥80% , FEVІ/FVC < 70% - As a rule chronic cough with sputum

II, moderate 

50%< FEVІ < 80% - FEVІ/FVC < 70% - Symptoms are more significant, presence of dyspnea during physical activity and exacerbation

III, severe 

30%< FEVІ < 50% FEVІ/FVC < 70% - Symptoms cause worsening of life quality

IV, very severe FEVІ < 30% FEVІ/FVC < 70% and CRF

Page 24: Chronic Obstructive Pulmonary Disease (COPD)

Increasing of intensivity of treatment in correlation with COPD severity;

Permanent basis therapy; Individual sensitivity of patients to

different medicines leads to necessarity of permanent control;

Inhaled medicines are useful.

Page 25: Chronic Obstructive Pulmonary Disease (COPD)
Page 26: Chronic Obstructive Pulmonary Disease (COPD)
Page 27: Chronic Obstructive Pulmonary Disease (COPD)
Page 28: Chronic Obstructive Pulmonary Disease (COPD)

Short action – (Ipratropium bromid, Berodual Н) has more slowly beginning but longer action than β2-agonists

Prolonged action – (Thyotropium bromid, Spiriva ) is active for 24 hours

2-agonists of short action (Salbutamol, Fenoterol) – fast beginning of action, but duration – 4-6 hours

2-agonists of prolonged action (Salmeterol, Formoterol ) are active for 12 hours.

Methylxantines Theophyllines of prolonged action are useful –

Teopec, Teotard.

Page 29: Chronic Obstructive Pulmonary Disease (COPD)

Are useful for permanent basis therapy for patients with COPD III-IV st.

Inhaled GCS are used. Prednisone may be used only during

exacerbation and is not recommended for basis therapy

Inhaled GCS (Beclomethasone, Budesonid, Fluticasone).

Seretid (GCS+Salmeterol) is used in patients with III-IV st. of COPD and oftern exacerbations in anamnesis.

Page 30: Chronic Obstructive Pulmonary Disease (COPD)
Page 31: Chronic Obstructive Pulmonary Disease (COPD)

Thanks for your attention!


Recommended